Meiragtx Holdings Plc (MGTX) Stock Price, Quote & News

Company Profile

MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 radiation-induced xerostomia, as well as in Phase ½ trial for Sjogren's syndrome; AAV-GAD in Phase 2...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 860 7985

Website: meiragtx.com

Address:

655 Third Avenue, Suite 1115, New York, United States

ErnieWorthing84 Jan. 13 at 7:07 PM

$MGTX The riboleptin program aims to topple metreleptin, which is now owned by Chiesi (private). Can't find up to date figures, but 2021 sales were around 140 mil

0 · Reply

ErnieWorthing84 Jan. 13 at 7:01 PM

$MGTX New deck. Genetic obesity in pipeline (part of Hologen JV). More commercial research on xero potential, it looks like https://meiragtx.gcs-web.com/static-files/e5c3e08b-abd6-4390-92cf-3ee69c448810

2 · Reply

Bogy99 Jan. 13 at 2:27 PM

$MGTX these shorts are getting brazen. Now short 5.2mm shares. New record. I sure hope there is any good news soon. Would cause a significant short squeeze. Would feel very bad for those shorts. Pray for their families !!

1 · Reply

ErnieWorthing84 Jan. 12 at 8:38 PM

$MGTX So as not to be ONLY positive and pumpy here, I'm expecting that Xero will be further delayed. The appear not to have finished enrolling :( https://www.linkedin.com/posts/side-effect-support-llc_do-you-or-someone-you-love-suffer-from-moderate-activity-7415785995939303425-0Q72?utm_source=share&utm_medium=member_desktop&rcm=ACoAAA-izPIBXISQ360qmHAvSKAoz0ecqKOipGs

3 · Reply

vu_jade Jan. 12 at 7:37 PM

$MGTX the worst thing I could say about MGTX here is they have to many partnerships Added

1 · Reply

ErnieWorthing84 Jan. 12 at 3:50 PM

$MGTX 🧐

1 · Reply

vu_jade Jan. 12 at 3:21 PM

$MGTX the games with this name

0 · Reply

slinghook67 Jan. 12 at 1:36 PM

$MGTX To show how fast things can change in Biotech, and to validate how undervalued MeiraGTx truly is, take a look at Abivax. They have 1 late stage Phase 3 asset for UC and their market cap was ~$400M 9 months ago (share price ~$5). With projected sales of $500-$1.5B within 5 years, and fantastic Phase 3 efficacy, their market cap today is $8.9B and the Wall Street Journal is reporting today that Eli Lilly is preparing a bid to acquire them for $17.5B. So, from $400M to $17.5B in ~9 months. Absolutely unbelievable.

1 · Reply

slinghook67 Jan. 12 at 3:17 AM

$MGTX This is a positive tailwind for Meira......

1 · Reply

vu_jade Jan. 11 at 12:41 AM

$MGTX sound more Homework .. this is a $50 biotech company trading under $10

2 · Reply

Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx Conference

Nov 13, 2025, 8:00 AM EST - 2 months ago

MeiraGTx Reports Third Quarter 2025 Financial and Operational Results

Nov 12, 2025, 3:30 PM EST - 2 months ago

MeiraGTx: Latest Eli Lilly Partnership Ignites Riboswitch Technology Potential

Nov 10, 2025, 9:10 AM EST - 2 months ago

Eli Lilly signs deal for MeiraGTx's gene therapy for severe eye disease

LLY

Nov 10, 2025, 7:00 AM EST - 2 months ago

MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology

Oct 7, 2025, 8:00 AM EDT - 3 months ago

MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

Sep 25, 2025, 3:48 AM EDT - 3 months ago

MeiraGTx: Hologen Partnership Makes Parkinson's Gene Therapy Vital

Aug 14, 2025, 8:00 AM EDT - 5 months ago

MeiraGTx Reports Second Quarter 2025 Financial and Operational Results

May 13, 2025, 4:30 PM EDT - 8 months ago

MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

May 13, 2025, 8:00 AM EDT - 8 months ago

MeiraGTx Reports First Quarter 2025 Financial and Operational Results

May 9, 2025, 8:00 AM EDT - 8 months ago

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease

Apr 29, 2025, 7:11 AM EDT - 9 months ago

Cone Rod Dystrophy Market Report 2025-2030, with Profiles of SparingVision, Beacon Therapeutics, Nanoscope Therapeutics, MeiraGTx, Ascidian Therapeutics, jCyte, BlueRock Therapeutics and more

Mar 25, 2025, 10:50 AM EDT - 10 months ago

MeiraGTx Holdings: Gaining Regulatory Focus

Mar 13, 2025, 9:51 AM EDT - 10 months ago

MeiraGTx Collaborates With Hologen AI To Expedite Development Of Parkinson's Candidate, Stock Soars

Mar 13, 2025, 8:00 AM EDT - 10 months ago

MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates

Mar 13, 2025, 7:30 AM EDT - 10 months ago

MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson's Disease and Industrialize MeiraGTx's Proprietary Manufacturing Process

Feb 21, 2025, 6:30 AM EST - 11 months ago

MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy

Jan 22, 2025, 4:09 PM EST - 1 year ago

MeiraGTx: 2 Possible Near-Term BLA Filings Could Ignite Shareholder Value

Jan 22, 2025, 8:30 AM EST - 1 year ago

MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations

Dec 3, 2024, 2:18 PM EST - 1 year ago

MeiraGTx Holdings: Behind The Recent Rally

Oct 15, 2024, 1:32 PM EDT - 1 year ago

MeiraGTx: Positive PD Data Moves Needle Forward For Regulatory Meetings

Oct 9, 2024, 4:30 PM EDT - 1 year ago

MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference

Aug 12, 2024, 7:05 AM EDT - 1 year ago

MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results

Aug 12, 2024, 7:03 AM EDT - 1 year ago

MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi

Jul 15, 2024, 11:02 AM EDT - 1 year ago

MeiraGTx: A Very Attractive Longer-Term Play, With Potential Near-Term Catalysts

May 9, 2024, 8:00 AM EDT - 1 year ago

MeiraGTx Reports First Quarter 2024 Financial and Operational Results

Apr 24, 2024, 4:30 PM EDT - 1 year ago

MeiraGTx to Participate in Upcoming Investor Conferences

Apr 18, 2024, 4:30 PM EDT - 1 year ago

MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference

Mar 14, 2024, 8:30 AM EDT - 1 year ago

MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates

Feb 15, 2024, 8:23 AM EST - 2 years ago

MeiraGTx: Bota-Vec Program Advancing With Milestones Being Met

Dec 21, 2023, 7:00 AM EST - 2 years ago

MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million

Nov 14, 2023, 8:00 AM EST - 2 years ago

MeiraGTx Announces Third Quarter 2023 Financial and Operational Results

Oct 30, 2023, 8:28 AM EDT - 2 years ago

MeiraGTx shares jump as Sanofi invests in gene therapy

SNY

Oct 30, 2023, 7:30 AM EDT - 2 years ago

MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities

Oct 24, 2023, 8:30 AM EDT - 2 years ago

MeiraGTx Announces an Oral Presentation and Eight Posters at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress

Aug 10, 2023, 8:00 AM EDT - 2 years ago

MeiraGTx Reports Second Quarter 2023 Financial and Operational Results

Aug 1, 2023, 9:10 AM EDT - 2 years ago

MeiraGTx Announces Poster Presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-Oncology

Jul 19, 2023, 8:30 AM EDT - 2 years ago

MeiraGTx Announces its Wholly-Owned Gene Therapy Manufacturing Facility in Shannon, Ireland has Received Commercial MIA Authorization for QC Testing

Jun 27, 2023, 7:30 AM EDT - 2 years ago

MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

Jun 22, 2023, 4:01 PM EDT - 2 years ago

MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Company's Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June 27,

May 11, 2023, 8:00 AM EDT - 2 years ago

MeiraGTx Reports First Quarter 2023 Financial and Operational Results

May 3, 2023, 8:30 AM EDT - 2 years ago

MeiraGTx Announces $60 Million Private Placement of Ordinary Shares

Apr 21, 2023, 8:30 AM EDT - 2 years ago

MeiraGTx Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting

Mar 14, 2023, 8:00 AM EDT - 3 years ago

MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial and Operational Results

Dec 8, 2022, 4:30 PM EST - 3 years ago

MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022

Oct 4, 2022, 8:00 AM EDT - 3 years ago

MeiraGTx Announces the Upcoming Presentation of 15 Abstracts at the European Society of Gene and Cell Therapy (ESGCT) 2022 Annual Congress

Oct 1, 2022, 10:00 AM EDT - 3 years ago

Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigmentosa (XLRP)

Sep 16, 2022, 2:00 AM EDT - 3 years ago

MeiraGTx's Industry-Leading Gene Therapy Manufacturing Facility in Shannon, Ireland Formally Introduced by Head of Irish Government

Aug 11, 2022, 8:30 AM EDT - 3 years ago

MeiraGTx Reports Second Quarter 2022 Financial and Operational Results

Aug 3, 2022, 8:00 AM EDT - 3 years ago

MeiraGTx Announces Financing Agreement with Perceptive Advisors for Up to $100 Million Secured by Manufacturing Facilities

ErnieWorthing84 Jan. 13 at 7:07 PM

$MGTX The riboleptin program aims to topple metreleptin, which is now owned by Chiesi (private). Can't find up to date figures, but 2021 sales were around 140 mil

0 · Reply

ErnieWorthing84 Jan. 13 at 7:01 PM

2 · Reply

Bogy99 Jan. 13 at 2:27 PM

1 · Reply

ErnieWorthing84 Jan. 12 at 8:38 PM

3 · Reply

vu_jade Jan. 12 at 7:37 PM

$MGTX the worst thing I could say about MGTX here is they have to many partnerships Added

1 · Reply

ErnieWorthing84 Jan. 12 at 3:50 PM

$MGTX 🧐

1 · Reply

vu_jade Jan. 12 at 3:21 PM

$MGTX the games with this name

0 · Reply

slinghook67 Jan. 12 at 1:36 PM

1 · Reply

slinghook67 Jan. 12 at 3:17 AM

$MGTX This is a positive tailwind for Meira......

1 · Reply

vu_jade Jan. 11 at 12:41 AM

$MGTX sound more Homework .. this is a $50 biotech company trading under $10

2 · Reply

ErnieWorthing84 Jan. 9 at 10:30 PM

$MGTX This one is worth revisiting once a year (recall that Sanofi acquired Zandy’s previous outfit, Kadmon). https://www.fiercebiotech.com/biotech/sanofi-pays-30m-first-look-meiragtxs-data-and-shot-brew-deals

2 · Reply

Mikelonggggggggg Jan. 9 at 5:37 PM

$MGTX

1 · Reply

Helpmrwizard Jan. 9 at 3:30 AM

$MGTX filed selling plan seems to hit about the same time every quarter: bought my monthly allotment today, by chance. Will continue my monthly purchases while under $15/ share; holding to at least $32 maybe a lot higher as long as they are not acquired

1 · Reply

slinghook67 Jan. 8 at 11:05 PM

$MGTX Here’s my simple take on my MeiraGTx investment. While it equally amazes and frustrates me that we’re so undervalued, I remind myself daily that it's completely meaningless that there's no retail interest, broad hedge fund or mutual fund interest, what matters and what's most consequential, is that the absolute smartest guys in the room have 100% knowledge of what Meira has built - and they all want it. Name a biotech out there that has the likes of J&J, Sanofi, Eli Lilly, Eric Schmidt, and Joseph Edelman heavily invested. Meira stands alone in that regard and I wish anyone luck that's going to bet against that cohort.

2 · Reply

vu_jade Jan. 8 at 8:02 PM

$MGTX another weak volume drop

1 · Reply

ErnieWorthing84 Jan. 8 at 4:08 PM

$MGTX

1 · Reply

Mikelonggggggggg Jan. 8 at 3:57 PM

$MGTX

0 · Reply

slinghook67 Jan. 8 at 12:49 AM

$MGTX In an effort to get a conversation going, I am proposing a hypothetical scenario for everyone to vote on: Pretend you're a MeiraGTx board member and Eli Lilly has made a bid to acquire Meira for$2B. The offer is framed as$15 per share now and then 2 CVR's at $5 each, payable for BLA filings no later than 12/31/27 for Xerostomia and Parkinson's respectively. If both BLA's are filed the total amount paid per share is $25 or ~$2B. If neither get filed shareholders only get their previously paid $15 per share. Do you vote yes or no for this offer?

4 · Reply

DougAfter60 Jan. 7 at 8:03 PM

$MGTX nice day

0 · Reply

ErnieWorthing84 Jan. 7 at 3:12 PM

$MGTX Come back to papa

0 · Reply

vu_jade Jan. 7 at 3:11 PM

$MGTX pure manipulation..

0 · Reply

vu_jade Jan. 6 at 8:23 PM

Sometimes you’re just mush … since my first purchase 12/15 $MGTX has gone down 10/15 days … Talk about horrible timing Sorry longs

1 · Reply

Market Cap	582.76M
Revenue (ttm)	33.28M
Net Income (ttm)	-147.79M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-444.08%
Debt to Equity Ratio	0.00

Volume	255,800
Avg Vol	559,780
Day's Range	N/A - N/A
Shares Out	80.49M
Stochastic %K	30%
Beta	1.38
Analysts	Strong Sell
Price Target	$23.43